Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.66

(-2.24%)

EBITDA Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual EBITDA in 2023 was -28.35 Million EUR , down -0.67% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly EBITDA in 2024 Q2 was -13.76 Million EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported an annual EBITDA of -28.17 Million EUR in 2022, down -129.18% from previous year.
  • Vivoryon Therapeutics N.V. reported an annual EBITDA of -12.03 Million EUR in 2021, up 20.35% from previous year.
  • Vivoryon Therapeutics N.V. reported a quarterly EBITDA of -10.61 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported a quarterly EBITDA of N/A for 2023 FY, down -0.67% from previous quarter.

Annual EBITDA Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual EBITDA of Vivoryon Therapeutics N.V. (2023 - 2011)

Year EBITDA EBITDA Growth
2023 -28.35 Million EUR -0.67%
2022 -28.17 Million EUR -129.18%
2021 -12.03 Million EUR 20.35%
2020 -16.34 Million EUR -106.49%
2019 -7.62 Million EUR 0.23%
2018 -7.67 Million EUR 21.86%
2017 -9.85 Million EUR 28.37%
2016 -13.68 Million EUR -2.85%
2015 -13.33 Million EUR -19.76%
2014 -11.17 Million EUR -19.78%
2013 -9.33 Million EUR 8.37%
2012 -10.18 Million EUR 26.11%
2011 -13.77 Million EUR 0.0%

Peer EBITDA Comparison of Vivoryon Therapeutics N.V.

Name EBITDA EBITDA Difference
Boiron SA 80.67 Million EUR 135.143%
Laboratorios Farmaceuticos Rovi, S.A. 238.01 Million EUR 111.912%
Vetoquinol SA 104.58 Million EUR 127.111%
Valneva SE -64.51 Million EUR 56.053%
AB Science S.A. -9.28 Million EUR -205.495%
Nanobiotix S.A. -34.01 Million EUR 16.655%
PHAXIAM Therapeutics S.A. -22.93 Million EUR -23.65%
BioSenic S.A. -6.79 Million EUR -317.201%
ABIVAX Société Anonyme -133.2 Million EUR 78.715%
Formycon AG 81.05 Million EUR 134.981%